Immunocore Holdings plc American Depositary Shares (IMCR) Stock
Key stats
- Market cap
- $1.65B
- Price / Earnings ratio
- -91.4x
- EPS (TTM)
- -$1.29
- Volume
- Loading
- 52-week high
- $40.71
- 52-week low
- $27.50
Source: third-party data provider, as of October 23, 2026
Compare with IMCR
Recent news
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
IMCR
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
IMCR
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
IMCR
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?
IMCRNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 57.65
- MACD 12/26/9
- -0.32
- EMA 9 of MACD
- -0.86
- MACD histogram
- 0.53
- SMA 50
- $32.85
- Price below SMA 50
- EMA 50
- $31.70
- Price above EMA 50
- SMA 200
- $31.81
- Price above SMA 200
- EMA 200
- $32.52
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
IMCRWill Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
IMCRIMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
IMCRIs IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?
IMCR
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss
IMCR
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
IMCR
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
IMCR
Immunocore Q2 Earnings Call Highlights
Immunocore Q2 Earnings Call Highlights
IMCR
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead
IMCR
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?
IMCRNews tone: automated (AI) classification of the article's content, not a price prediction.
About Immunocore Holdings plc American Depositary Shares
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Bahija Jallal Ph.D. | CEO & Executive Director | 1961 |
| Mr. Travis Alan Coy M.B.A. | CFO, Executive VP & Head of Corporate Development | 1980 |
| Dr. Kripa Ram Ph.D. | Executive VP & Chief Operating Officer | 1963 |
| Mr. John Goll III | SVP, Finance & Chief Accounting Officer | — |
| Ms. Annelise Vuidepot Ph.D. | Chief Science and Technology Officer & Milton Park Site Head | — |
| Mr. Sean D. Buckley | VP & Chief Information Officer | 1983 |
| Mr. Ryan Baker | Vice President of Investor Relations | — |
| Ms. Lily Margaret Hepworth | Executive VP, General Counsel & Company Secretary | 1983 |
| Ms. Elizabeth Varki Jobes Esq., J.D. | Chief Compliance Officer | 1967 |
| Mr. Sébastien Desprez | Vice President of Communications | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 23, 2026
Technical indicators
- RSI 14
- 57.65
- MACD 12/26/9
- -0.32
- EMA 9 of MACD
- -0.86
- MACD histogram
- 0.53
- SMA 50
- $32.85
- Price below SMA 50
- EMA 50
- $31.70
- Price above EMA 50
- SMA 200
- $31.81
- Price above SMA 200
- EMA 200
- $32.52
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $35.00
- Average
- $42.50
- High
- $50.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.4 | -2.2 | -7.7 | -7.9 | +2.6 | +9.0 | +6.8 | +12.0 | -17.8 | +5.1 |
